Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 42
Filter
3.
ESMO Open ; 6(2): 100054, 2021 04.
Article in English | MEDLINE | ID: mdl-33601296

ABSTRACT

BACKGROUND: We evaluated the efficacy and safety of the nontaxane microtubule dynamics inhibitor eribulin plus the humanized anti-VEGF monoclonal antibody bevacizumab in a novel second-line chemotherapy scheme in HER2-negative metastatic breast cancer (MBC) patients progressing after first-line paclitaxel and bevacizumab. PATIENTS AND METHODS: This is a multicenter, single-arm, Simon's two-stage, phase II study. The primary endpoint was the overall response rate, considered as the sum of partial and complete response based on the best overall response rate (BORR). The secondary endpoints were progression-free survival (PFS), overall survival (OS), and clinical benefit rate. RESULTS: A total of 58 of the 61 patients enrolled in the study were evaluable for efficacy. The BORR was 24.6% (95% CI 14.5-37.3). The clinical benefit rate was 32.8% (95% CI 21.3-46.0). The median PFS was 6.2 months (95% CI 4.0-7.8), and median OS was 14.8 months (95% CI 12.6-22.8). Overall, adverse events (AEs) were clinically manageable and the most common AEs were fatigue, paresthesia, and neutropenia. Quality of life was well preserved in most patients. CONCLUSIONS: The results of this study suggest that second-line therapy with bevacizumab in combination with eribulin has a meaningful clinical activity and may represent a potential therapeutic option for patients with HER2-negative MBC.


Subject(s)
Breast Neoplasms , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bevacizumab/therapeutic use , Breast Neoplasms/drug therapy , Female , Furans , Humans , Ketones , Paclitaxel/adverse effects , Quality of Life , Treatment Outcome
4.
Ann Oncol ; 29(7): 1497-1508, 2018 07 01.
Article in English | MEDLINE | ID: mdl-29873695

ABSTRACT

Background: The role of platinum-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients is highly controversial and it is not endorsed by current guidelines. Our meta-analysis aimed to better elucidate its activity, efficacy and safety. Material and methods: A systematic search of Medline, Web of Science and conferences proceedings up to 30 October 2017 was carried out to identify randomized controlled trials (RCTs) investigating platinum-based versus platinum-free neoadjuvant chemotherapy in TNBC patients. Using the fixed and random effects models, pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CI) were calculated for pathological complete response (pCR, defined as ypT0/is pN0), event-free survival (EFS), overall survival (OS) and grade 3 and 4 adverse events (AEs: neutropenia, anemia, thrombocytopenia and neuropathy). Results: Nine RCTs (N = 2109) were included. Overall, platinum-based neoadjuvant chemotherapy significantly increased pCR rate from 37.0% to 52.1% (OR 1.96, 95% CI 1.46-2.62, P < 0.001). Platinum-based neoadjuvant chemotherapy remained significantly associated with increased pCR rate also after restricting the analysis to the three RCTs (N = 611) that used the same standard regimen in both groups of weekly paclitaxel (with or without carboplatin) followed by anthracycline and cyclophosphamide (OR 2.53, 95% CI 1.37-4.66, P = 0.003). Conversely, among the 96 BRCA-mutated patients included in two RCTs, the addition of carboplatin was not associated with significantly increased pCR rate (OR 1.17, 95% CI 0.51-2.67, P = 0.711). Two RCTs (N = 748) reported survival outcomes: no significant difference in EFS (HR 0.72, 95% CI 0.49-1.06, P = 0.094) and OS (HR 0.86, 95% CI 0.46-1.63, P = 0.651) was observed. A significant higher risk of grade 3 and 4 hematological AEs, with no increased risk of grade 3 and 4 neuropathy was observed with platinum-based neoadjuvant chemotherapy. Conclusion: In TNBC patients, platinum-based neoadjuvant chemotherapy is associated with significantly increased pCR rates at the cost of worse hematological toxicities. Platinum-based neoadjuvant chemotherapy may be considered an option in TNBC patients. PROSPERO registration number: CRD42018080042.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Neoadjuvant Therapy , Organoplatinum Compounds/therapeutic use , Triple Negative Breast Neoplasms/drug therapy , Chemotherapy, Adjuvant , Female , Humans , Prognosis , Triple Negative Breast Neoplasms/pathology
5.
Breast ; 33: 104-108, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28360014

ABSTRACT

BACKGROUND: Although in clinical practice adjuvant chemotherapy (CT) and endocrine therapy (ET) are administered sequentially in patients with hormone-receptor positive breast cancer, the optimal timing, i.e. concurrent or sequential administration, of these treatments has been scarcely investigated. To better clarify this issue we conducted a systematic review and meta-analysis of randomized studies comparing these two modalities of administrations in terms of disease-free survival (DFS) and overall survival (OS). METHODS: Relevant studies were identified by searching PubMed, Web of Knowledge and the proceedings of the major conferences with no date restriction up to March 2016. The summary risk estimates (pooled hazard ratio [HR] and 95% confidence intervals [CI]) for DFS and OS were calculated using random effect models (DerSimonian and Laird method). RESULTS: A total of three randomized studies were eligible including 2021 breast cancer patients. Overall, 755 DFS events were observed, 365 in the sequential arm and 390 in the concomitant arm, with a pooled HR of 0.95 (95% CI = 0.76 to 1.18, P = 0.643). No association between timing of treatment and OS was observed (HR = 0.95; 95% CI = 0.80 to 1.12, P = 0.529). CONCLUSION: Our pooled analysis showed no association between the timing of administration of adjuvant CT and ET and DFS and OS in breast cancer patients candidates for both adjuvant treatments. Because of the small number of published trials, the lack of data on the timing with modern adjuvant treatments, i.e. taxane-containing CT and aromatase inhibitors, this topic remain still controversial and requires further studies to be clarified.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Aromatase Inhibitors/administration & dosage , Breast Neoplasms/drug therapy , Chemotherapy, Adjuvant/methods , Tamoxifen/administration & dosage , Aged , Breast Neoplasms/chemistry , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Bridged-Ring Compounds/administration & dosage , Disease-Free Survival , Drug Administration Schedule , Female , Humans , Middle Aged , Neoplasm Staging , Randomized Controlled Trials as Topic , Receptor, ErbB-2/analysis , Survival Rate , Taxoids/administration & dosage , Time Factors
6.
Ann Oncol ; 26(12): 2408-19, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26347105

ABSTRACT

BACKGROUND: The role of temporary ovarian suppression with luteinizing hormone-releasing hormone agonists (LHRHa) in the prevention of chemotherapy-induced premature ovarian failure (POF) is still controversial. Our meta-analysis of randomized, controlled trials (RCTs) investigates whether the use of LHRHa during chemotherapy in premenopausal breast cancer patients reduces treatment-related POF rate, increases pregnancy rate, and impacts disease-free survival (DFS). METHODS: A literature search using PubMed, Embase, and the Cochrane Library, and the proceedings of major conferences, was conducted up to 30 April 2015. Odds ratios (ORs) and 95% confidence intervals (CIs) for POF (i.e. POF by study definition, and POF defined as amenorrhea 1 year after chemotherapy completion) and for patients with pregnancy, as well hazard ratios (HRs) and 95% CI for DFS, were calculated for each trial. Pooled analysis was carried out using the fixed- and random-effects models. RESULTS: A total of 12 RCTs were eligible including 1231 breast cancer patients. The use of LHRHa was associated with a significant reduced risk of POF (OR 0.36, 95% CI 0.23-0.57; P < 0.001), yet with significant heterogeneity (I(2) = 47.1%, Pheterogeneity = 0.026). In eight studies reporting amenorrhea rates 1 year after chemotherapy completion, the addition of LHRHa reduced the risk of POF (OR 0.55, 95% CI 0.41-0.73, P < 0.001) without heterogeneity (I(2) = 0.0%, Pheterogeneity = 0.936). In five studies reporting pregnancies, more patients treated with LHRHa achieved pregnancy (33 versus 19 women; OR 1.83, 95% CI 1.02-3.28, P = 0.041; I(2) = 0.0%, Pheterogeneity = 0.629). In three studies reporting DFS, no difference was observed (HR 1.00, 95% CI 0.49-2.04, P = 0.939; I(2) = 68.0%, Pheterogeneity = 0.044). CONCLUSION: Temporary ovarian suppression with LHRHa in young breast cancer patients is associated with a reduced risk of chemotherapy-induced POF and seems to increase the pregnancy rate, without an apparent negative consequence on prognosis.


Subject(s)
Antineoplastic Agents, Hormonal/adverse effects , Fertility/drug effects , Gonadotropin-Releasing Hormone/agonists , Ovary/drug effects , Primary Ovarian Insufficiency/drug therapy , Randomized Controlled Trials as Topic/methods , Female , Fertility/physiology , Gonadotropin-Releasing Hormone/metabolism , Humans , Ovary/metabolism , Pregnancy , Primary Ovarian Insufficiency/chemically induced , Primary Ovarian Insufficiency/metabolism
9.
Healthc Financ Manage ; 48(6): 48, 50-2, 1994 Jun.
Article in English | MEDLINE | ID: mdl-10146032

ABSTRACT

If the healthcare industry automates clinical practices and links them along critical care pathways, will it be providing Federal regulators with data they may use to legislate how hospital care should be delivered? This article examines the implications of expanded use of increasingly sophisticated information systems in health care.


Subject(s)
Clinical Protocols , Cost Control/legislation & jurisprudence , Facility Regulation and Control/trends , Hospital Information Systems/legislation & jurisprudence , Legislation, Medical/trends , Facility Regulation and Control/economics , Humans , Long-Term Care/standards , Nursing Homes/legislation & jurisprudence , Patient Care Planning/legislation & jurisprudence , Patient Care Planning/standards , United States
10.
Healthc Financ Manage ; 46(6): 56, 58, 60 passim, 1992 Jun.
Article in English | MEDLINE | ID: mdl-10145641

ABSTRACT

Hospital information systems can support physician recruitment activities by helping identify the type of physician the institution needs, describe the type of medical practice a physician can expect, support the institution's strategic plan for the future, and demonstrate the institution's ability to assist a physician with his or her office billing and other administrative functions.


Subject(s)
Hospital Information Systems , Hospitals, Rural , Medical Staff, Hospital/supply & distribution , Personnel Selection/organization & administration , Career Choice , Data Collection , Decision Making , Decision Support Systems, Management , Hospitals, Rural/organization & administration , Medical Staff, Hospital/standards , Online Systems , Practice Management, Medical , Professional Practice Location , Role , United States , Workforce
12.
Nephron ; 61(1): 54-7, 1992.
Article in English | MEDLINE | ID: mdl-1528341

ABSTRACT

We studied the significance of free erythrocyte protoporphyrin (FEP) in relation to iron status, aluminum levels and anemia in uremic patients on chronic dialysis. All but 1 patient showed high FEP values closely related to the degree of anemia. Increased FEP levels are due to a defective heme synthesis, not related to iron deficiency or aluminum overload. Treatment of anemia with recombinant human erythropoietin reduced FEP values. We therefore hypothesize that recombinant human erythropoietin ameliorates an enzymatic defect in heme synthesis.


Subject(s)
Anemia/etiology , Erythrocytes/metabolism , Erythropoietin/therapeutic use , Protoporphyrins/blood , Renal Dialysis/adverse effects , Uremia/therapy , Aluminum/blood , Anemia/blood , Anemia/drug therapy , Erythrocytes/drug effects , Female , Ferritins/blood , Humans , Male , Middle Aged , Recombinant Proteins/therapeutic use
16.
Comput Nurs ; 8(6): 256-60, 1990.
Article in English | MEDLINE | ID: mdl-2268806

ABSTRACT

Installation and use of microcomputer LANs is on the rise in health care facilities. The microprocessor is becoming more powerful each day. The microcomputer is quite adept at handling textual and graphic information, which is a major requirement of any nursing patient information system. Microcomputer technology has now advanced to a level where a handful of hospitals have installed, and many hospitals actively plan to install, a complete nursing system based entirely upon a network of microcomputers. This paper discusses components of an order entry/results reporting/care management system based on a distributed, micro network architecture; the benefits of such a design; and the future technology to aid in system use and growth.


Subject(s)
Hospital Information Systems , Microcomputers/statistics & numerical data , Nursing Records , Computer Communication Networks , Humans , Microcomputers/economics , Software
18.
Am J Kidney Dis ; 12(6): 487-91, 1988 Dec.
Article in English | MEDLINE | ID: mdl-3143260

ABSTRACT

The efficacy and safety of calcium carbonate as a phosphate binder was evaluated in 20 patients on chronic hemodialysis who had previously received aluminum hydroxide. During the control period the patients were on aluminum hydroxide and calcitriol therapy and had plasma phosphorus levels less than 6 mg/dL (4.95 +/- 0.8 mg/dL). Aluminum hydroxide was then discontinued and no phosphate binder was prescribed for 1 month. Every patient developed hyperphosphatemia so that calcium carbonate treatment was begun and calcitriol dose was adjusted in relation to plasma calcium changes. After 24 months of calcium carbonate therapy, plasma phosphorus was 4.85 +/- 0.7 mg/dL, using a daily dose of calcium carbonate of 2.57 +/- 1.3 g (range, 1 to 6 g). The daily dose per patient of calcitriol was not different from that prescribed during the control period, but in five patients calcitriol was permanently withdrawn for hypercalcemia. At the end of the study plasma calcium, magnesium, bicarbonate, alkaline phosphatase, and parathyroid hormone values were unchanged in comparison with the control period, whereas a significant reduction in plasma aluminum and plasma aluminum increase induced by deferoxamine infusion was observed. The frequency of hypercalcemic and hyperphosphatemic episodes during the last 12 months of calcium carbonate therapy (6.2% and 16.6%, respectively) was not different from that observed during the 12 months on aluminum hydroxide therapy preceding the control period (4.5% and 14.7%, respectively). It was concluded that calcium carbonate is effective in the control of hyperphosphatemia and secondary hyperparathyroidism in patients on chronic hemodialysis and that the incidence of hypercalcemia is low when the daily dosage is less than 6 g.


Subject(s)
Calcium Carbonate/therapeutic use , Hyperparathyroidism, Secondary/prevention & control , Kidney Failure, Chronic/complications , Adult , Aluminum/blood , Aluminum Hydroxide/therapeutic use , Blood Chemical Analysis , Calcitriol/therapeutic use , Calcium Carbonate/adverse effects , Female , Humans , Hyperparathyroidism, Secondary/etiology , Kidney Failure, Chronic/therapy , Long-Term Care , Male , Middle Aged , Phosphates/blood , Renal Dialysis
19.
Healthc Comput Commun ; 5(6): 18-20, 1988 Jun.
Article in English | MEDLINE | ID: mdl-10287611

ABSTRACT

Health Micro Data Systems (HMDS), headed by Frank Poggio, president, is headquartered in Madison WI, with more than 40 employees in the home office in Madison and the sales and support office in San Francisco. The firm generates approximately $2.6 million a year strictly with microcomputer based systems for healthcare facilities. Recently, HC&C Editor/Publisher Bill W. Childs had the opportunity to speak with Poggio about HMDS, the firm's role in the industry and some challenges for the present and the future.


Subject(s)
Computers , Contract Services , Financial Management , Hospital Information Systems , Industry , Microcomputers , Wisconsin
SELECTION OF CITATIONS
SEARCH DETAIL
...